DrugPatentWatch Database Preview
SKELID Drug Profile
see a sample report or, see our see our flat-rate plans
Which patents cover Skelid, and when can generic versions of Skelid launch?
The generic ingredient in SKELID is tiludronate disodium. There is one drug master file entry for this compound. Additional details are available on the tiludronate disodium profile page.
Summary for SKELID
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Bulk Api Vendors: | 19 |
| Clinical Trials: | 1 |
| Patent Applications: | 804 |
| Formulation / Manufacturing: | see details |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for SKELID |
| DailyMed Link: | SKELID at DailyMed |
Synonyms for SKELID
| [[(4-Chlorophenyl)thio]methylene]biphosphonic Acid Disodium Salt |
| 149845-07-8 |
| 89987-06-4 (Parent) |
| AC1L1U6X |
| AC1NQL7O |
| AC1Q1UYI |
| AKOS015894005 |
| AN-6422 |
| API0004187 |
| BH6M93CIA0 |
| C7H8O6P2S.2Na |
| CAS-149845-07-8 |
| CHEMBL1200448 |
| Cl-TMBP |
| CTK8E8288 |
| D02285 |
| D4167 |
| Disodium (4-chlorophenylthio)methylenediphosphonate |
| disodium [(4-chlorophenyl)sulfanyl-[hydroxy(oxido)phosphoryl]methyl]-hydroxy-phosphinate |
| disodium [(4-chlorophenyl)sulfanyl-[hydroxy(oxido)phosphoryl]methyl]-hydroxyphosphinate |
| Disodium [[(4-Chlorophenyl)thio]methylene]bis(hydrogenphosphonate) |
| Disodium dihydrogen (((p-chlorophenyl)thio)methylene)diphosphonate |
| Disodium Tiludronate |
| DisodiumTiludronate |
| DSSTox_CID_28547 |
| DSSTox_GSID_48621 |
| DSSTox_RID_82819 |
| DTXSID1048621 |
| FT-0675237 |
| I04-8322 |
| J-008635 |
| KS-000017AP |
| LS-173356 |
| NCGC00182026-01 |
| OR223641 |
| Phosphonic acid, (((4-chlorophenyl)thio)methylene)bis-, disodium salt |
| RTX-010242 |
| SCHEMBL41053 |
| Skelid (TN) |
| sr 41319b |
| SR 41319G |
| SR-41319B |
| TILUDRONATE DISODIUM |
| Tiludronate disodium (USAN) |
| Tiludronate disodium [USAN] |
| Tiludronic acid disodium salt |
| TILUDRONIC ACID, DISODIUM SALT |
| TILUDRONIC ACID,DISODIUM SALT |
| Tox21_112961 |
| UNII-BH6M93CIA0 |
US Patents and Regulatory Information for SKELID
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | SKELID | tiludronate disodium | TABLET;ORAL | 020707-001 | Mar 7, 1997 | DISCN | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
Expired US Patents for SKELID
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | SKELID | tiludronate disodium | TABLET;ORAL | 020707-001 | Mar 7, 1997 | ➤ Sign Up | ➤ Sign Up |
| Sanofi Aventis Us | SKELID | tiludronate disodium | TABLET;ORAL | 020707-001 | Mar 7, 1997 | ➤ Sign Up | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
see a sample report or, see our see our flat-rate plans
